ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890 is on this study

  • The record lists it as a treatment, written “INCA33890”.
  • A model not recorded judged it tested: part of what the study tests. Nov 1, 2026, 6:35 AM UTC
  • The role rule says the same.
  • So Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890's page lists this study under “Testing it”.
3 links0 made here, not in the record5 judgments2 judges (the rules as one: Rule based)2 record changes seen
Model not recordedRule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07876414A Clinical Trial Comparingan Antibody (INCA33890)Versus Pembrolizumab forSquamous Cell Carcinoma ofthe Head and Neck.Groupe Oncologie RadiotherapiePhase 2 · not yet recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 15 · ClinicalTrials.gov record · Version of 2026-10-15Oct 22 · ClinicalTrials.gov record · Version of 2026-10-22Version of 2026-10-22CONDITIONSNeoplasms, Squamous CellNo longer in the registry's filing›As of now · Rule based · Main conditionMain conditionDRUGSAnti-PD-1/Anti-TGFbRII Bisp…Entry “INCA33890”, read by our name r…›Nov 1 · A model not recorded · TestedNov 18 · Rule based · TestedTestedPembrolizumabIntervention entry›Nov 1 · A model not recorded · ComparatorNov 18 · Rule based · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
2 versions of the record seen on ClinicalTrials.gov, Oct 15–Oct 22 · changes seen, not judgments
Nov 1Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890A model not recordedTestedCurrent
Nov 1PembrolizumabA model not recordedComparatorCurrent
Nov 18Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890Rule based · role ruleTestedAgrees
Nov 18PembrolizumabRule based · role ruleComparatorAgrees
As of nowNeoplasms, Squamous CellRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.